201 related articles for article (PubMed ID: 20733155)
1. Advances in the 5q- syndrome.
Boultwood J; Pellagatti A; McKenzie AN; Wainscoat JS
Blood; 2010 Dec; 116(26):5803-11. PubMed ID: 20733155
[TBL] [Abstract][Full Text] [Related]
2. 5q- syndrome.
Boultwood J; Pellagatti A; Wainscoat JS
Curr Pharm Des; 2012; 18(22):3180-3. PubMed ID: 22571696
[TBL] [Abstract][Full Text] [Related]
3. The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome.
Boultwood J
Pediatr Rep; 2011 Jun; 3 Suppl 2(Suppl 2):e10. PubMed ID: 22053272
[TBL] [Abstract][Full Text] [Related]
4. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
[TBL] [Abstract][Full Text] [Related]
5. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
6. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Dutt S; Narla A; Lin K; Mullally A; Abayasekara N; Megerdichian C; Wilson FH; Currie T; Khanna-Gupta A; Berliner N; Kutok JL; Ebert BL
Blood; 2011 Mar; 117(9):2567-76. PubMed ID: 21068437
[TBL] [Abstract][Full Text] [Related]
7. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
Kumar MS; Narla A; Nonami A; Mullally A; Dimitrova N; Ball B; McAuley JR; Poveromo L; Kutok JL; Galili N; Raza A; Attar E; Gilliland DG; Jacks T; Ebert BL
Blood; 2011 Oct; 118(17):4666-73. PubMed ID: 21873545
[TBL] [Abstract][Full Text] [Related]
8. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.
Barlow JL; Drynan LF; Hewett DR; Holmes LR; Lorenzo-Abalde S; Lane AL; Jolin HE; Pannell R; Middleton AJ; Wong SH; Warren AJ; Wainscoat JS; Boultwood J; McKenzie AN
Nat Med; 2010 Jan; 16(1):59-66. PubMed ID: 19966810
[TBL] [Abstract][Full Text] [Related]
9. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
Ebert BL
Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
[TBL] [Abstract][Full Text] [Related]
10. Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
Yip BH; Pellagatti A; Vuppusetty C; Giagounidis A; Germing U; Lamikanra AA; Roberts DJ; Fernandez-Mercado M; McDonald EJ; Killick S; Wainscoat JS; Boultwood J
Leukemia; 2012 Sep; 26(9):2154-8. PubMed ID: 22430631
[No Abstract] [Full Text] [Related]
11. A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure.
Ear J; Hsueh J; Nguyen M; Zhang Q; Sung V; Chopra R; Sakamoto KM; Lin S
J Genet Genomics; 2016 May; 43(5):307-18. PubMed ID: 27216296
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the 5q- Syndrome.
Pellagatti A; Boultwood J
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015037. PubMed ID: 26075044
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Lee JH; List A; Sallman DA
Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
[TBL] [Abstract][Full Text] [Related]
15. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.
Boultwood J; Yip BH; Vuppusetty C; Pellagatti A; Wainscoat JS
Adv Biol Regul; 2013 Jan; 53(1):8-17. PubMed ID: 23031788
[TBL] [Abstract][Full Text] [Related]
16. Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.
Vlachos A; Farrar JE; Atsidaftos E; Muir E; Narla A; Markello TC; Singh SA; Landowski M; Gazda HT; Blanc L; Liu JM; Ellis SR; Arceci RJ; Ebert BL; Bodine DM; Lipton JM
Blood; 2013 Oct; 122(14):2487-90. PubMed ID: 23943650
[TBL] [Abstract][Full Text] [Related]
17. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H
Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549
[TBL] [Abstract][Full Text] [Related]
18. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
19. Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
Boultwood J; Pellagatti A; Wainscoat JS
Adv Biol Regul; 2012 Jan; 52(1):196-203. PubMed ID: 21930148
[No Abstract] [Full Text] [Related]
20. Genetic deletions in AML and MDS.
Ebert BL
Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
